Day: June 4, 2021

We refer to previous announcements in Norwegian Finans Holding ASA and Bank Norwegian ASA regarding the ongoing merger process between Norwegian Finans Holding ASA and Bank Norwegian ASA, including announcement on May 11, 2021 regarding notice of Extraordinary General meeting (EGM) of shareholders in Norwegian Finans Holding ASA. The EGM in Norwegian Finans Holding ASA was held electronically on June 4, 2021, at 09.00 CET. All proposed resolutions on the agenda were approved, including the merger plan. Please find the minutes from the EGM in Norwegian Finans Holding ASA attached. As previously stated, the merger is considered to have no material effect nor adversely impact Norwegian Finans Holding ASA’s or Bank Norwegian ASA’s ability to fulfill its obligations towards creditors under relevant agreements, including current...

ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Anne Lesage, Ph.D., chief early development officer at Pharvaris, will present bradykinin challenge data supporting the pharmacokinetic (PK) and pharmacodynamic (PD) profile of PHA121 (PHA-022121) for the treatment of hereditary angioedema (HAE), at the 12th C1 Inhibitor Deficiency and Angioedema Workshop, to be held virtually June 3-6, 2021. “Pharvaris is proud to be a sponsor for the 12th C1 Inhibitor Deficiency and Angioedema Workshop,” said Dr. Lesage. “Findings presented here from pre-clinical and clinical...

Is market volatility concerning you? Do you want to ensure your investment portfolio is more resilient?Insider Corner, an information and educational service for investors, has launched an investment strategy newsletter known as Insider Weekly. Go to https://insidercorner.com for more information! With many investors growing uneasy about the stability of the stock market in the wake of the global pandemic, the recently launched Insider Weekly is published by seasoned fund managers as a means to provide you with professional investment research and analysis. Market volatility is again at the forefront of investors’ minds, with the upheaval of 2020 being just the latest in a string of destabilizing stock market events. However, as the cost of living continues to rise across the US, many also now rely on their investment portfolios to fund...

AB “Ignitis grupė” (hereinafter – ‘Company’ or ‘Ignitis Group’) informs that on 4 June 2021 it has received the letter of resignation from Dominykas Tučkus, Company’s Management Board Member and Business Development and Infrastructure Director, from the positions of Management Board Member and Business Development and Infrastructure Director at Ignitis Group as well as from all other official positions held at the companies owned by Ignitis Group (hereinafter – Group). Dominykas Tučkus will continue his career path abroad. Dominykas Tučkus’s last day in the office is 25 June 2021. The Company’s Supervisory Board was informed about the resignation of Dominykas Tučkus and decided against a selection of a new Member of the Management Board, stating that the remaining Management Board Members can ensure the continuity of operations and also...

Mechelen, Belgium; 4 June 2021; 07.01 CET; – Galapagos NV (Euronext & Nasdaq: GLPG) today announced that primary and secondary endpoint results from the phase 3 SELECTION induction and maintenance study (NCT02914522) were published in The Lancet (doi.org/10.1016/S0140-6736(21)00666-8). The study, sponsored by Gilead Sciences, Inc., was designed to assess the efficacy and safety of the once-daily, oral preferential JAK1 inhibitor, filgotinib, under investigation in patients with moderately to severely active ulcerative colitis (UC). In addition to the primary and secondary endpoints, which have been reported at the United European Gastroenterology congress in October 2020   and can be found on the Galapagos website, www.glpg.com/press-releases, the publication also reports data from a post-hoc analysis by induction cohort of filgotinib...

PORGERA, Papua New Guinea, June 04, 2021 (GLOBE NEWSWIRE) — The process of re-opening the Porgera gold mine under the terms of the binding framework agreement between the government and operator Barrick Niugini Limited (BNL) took a major step forward with a discussion between Barrick President and Chief Executive Mark Bristow, Prime Minister James Marape and the various Porgera Landowners groups and others here today.  The framework agreement provides that Porgera will be owned by a new joint venture held 51% by Papua New Guinea (PNG) stakeholders and 49% by BNL, with BNL continuing as the operator.  The framework agreement also calls on the Porgera Landowners and the Enga Province to have a dialogue to determine how the 10% ‘protected equity’ which forms part of PNG’s 51% interest will be allocated. Speaking at the event, which...

The city of dreams, Mumbai is everything you have ever dreamt of. It offers an opportunity to change your life and to live the life of your dreams. Whether you are new to the city or have been living here for many years, there is no joy like exploring the city on your two wheeler. Owning a two wheeler brings pride and thrill but if you are still wondering whether you want to buy one or not, now is the time to turn the dreams into a reality. You can own any two wheeler of your choice with two wheeler loans in Mumbai. Hero FinCorp offers the loan for every brand and type of two wheeler in the country. Simply scout the market for two wheelers and shortlist the ones that you are keen on buying. Whether this is your first two wheeler or you already own one, you must remember to take a test drive on it. Do not purchase the two wheeler without...

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancerSanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and Alliance Foundation Trials (AFT), which are world-leading academic groups delivering practice-changing breast cancer clinical research Collaborating on the Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s investigational amcenestrant in estrogen receptor-positive (ER+) patients who prematurely discontinue standard therapy and have high risk of disease recurrence Parties to finalize full terms of...